Endo, Novartis begin agreement

Share this article:

Endo Pharmaceuticals has entered into a licensing agreement with Novartis to obtain the exclusive US marketing rights for Voltaren Gel (diclofenac sodium topical gel) 1%. Endo said it expects to commercialize Voltaren Gel using one of its two specialty sales forces, consisting of 160 reps, prior to executing a full physician launch in late May with an additional 275 contract sales reps targeting primary care physicians who prescribe both NSAIDs and Cox-2s.

Voltaren Gel received FDA approval in October 2007. Endo estimates US peak annual sales for Voltaren Gel as an osteoarthritis pain treatment in the range of $250-300 million. 
Share this article:
You must be a registered member of MMM to post a comment.

Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

Upward Move: Jose Rivera

Upward Move: Jose Rivera

Jose Rivera. EVP, account director, Concentric